Jon P. Stonehouse, President, Chief Executive Officer of BioCryst
BioCryst bags $250M in a debt and royalty deal as the executive team preps a new drug launch for HAE
Three days after landing an FDA OK for their HAE drug berotralstat, BioCryst $BCRX now has some cash to see how far they can go …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
